Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03747367 · ClinicalTrials.gov registry record · NA
The Microbiome and Resilience to Sleep and Circadian Disruption
A NA study, sponsored by University of Colorado, Boulder.
- Completed
- Registry status
- NA
- Development phase
- 55
- Enrollment target
NCT03747367: Completed NA study, sponsored by University of Colorado, Boulder.
NCT03747367 is a NA study that has completed, run by University of Colorado, Boulder. The registered enrollment target is 55 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03747367, a NA study, has completed, sponsored by University of Colorado, Boulder.
- COMPLETED
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
Study Summary
This study is about how sleep loss and being awake at night impacts the ability to think, changes molecules in the blood, and alters the bacteria that live in the gut that typically help keep people healthy. This work will have important implications for the development of treatments and countermeasures for people who do not sleep enough and need to be active at different times of the day and night (e.g., emergency workers and military personnel).
Primary Outcome
Fecal "beta diversity" (unit=weighted UniFrac)
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Prebiotic
- BEHAVIORAL Insufficient Sleep
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2015-10-21 |
| Est. Completion | 2020-03-16 |
| Phase | NA |
What the finished NCT03747367 record still lists
NCT03747367 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03747367 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03747367 about?
NCT03747367 is a clinical study titled "The Microbiome and Resilience to Sleep and Circadian Disruption". This study is about how sleep loss and being awake at night impacts the ability to think, changes molecules in the blood, and alters the bacteria that live in the gut that typically help keep people healthy. This work will have important implications for the development of treatments and countermeas...
What is the current status of trial NCT03747367?
This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2015-10-21. Estimated completion is 2020-03-16.
What interventions are being tested in trial NCT03747367?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Prebiotic (DIETARY_SUPPLEMENT), Insufficient Sleep (BEHAVIORAL).
Who is sponsoring clinical trial NCT03747367?
This trial is sponsored by University of Colorado, Boulder, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03747367's enrollment target sits among peer trials
55 1264th of 2000 higher than 733 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI